Specialisation
Retina and Vitreous.
Full title
Phase III: Two-year, randomised, double-blind, multicentre, two-group trial comparing the efficacy and safety of 6 mg RTH258 compared to aflibercept in subjects with wet age-related macular degeneration.
Promoter
Alcon.
Start date
July 2015
End date
April 2018
Researchers
Principal: Dr Anniken Burés
